Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Recruiting Phase 1 Interventional

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

NCT06538558
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Tezampanel, Placebo
Drug
Lead sponsor
Proniras Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

NCT05375838
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1073, mRNA-1010, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
14
States / cities
Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Withdrawn Phase 2 Interventional

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

NCT06104358
View directory record Official record
Conditions
Diabete Type 2, Obesity
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

NCT02162758
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Dexlansoprazole, Dexlansoprazole Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Jacksonville, Florida • Chapel Hill, North Carolina • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Instructions in Nitrous Oxide Effects and Choice - 10

NCT00000258
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Nitrous oxide 10% & placebo, Nitrous oxide 20% & placebo, Nitrous oxide 30% & placebo, Nitrous oxide 40% and placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 32 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1997
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

NCT03309007
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
Metformin, Placebo Oral Tablet
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
30 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136
View directory record Official record
Conditions
No Evidence of Disease
Interventions
UV Light Therapy, Placebo, Celecoxib, Biopsy, Imaging Biomarker Analysis
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

NCT05458609
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lemborexant 10 mg, Naltrexone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

NCT00637793
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
NGX267
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phage 3Determination of Phage/Probiotic Synergistic Effects on Gastrointestinal Health

NCT05750433
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
PreforPro+B. subtilis DE111 probiotics, Placebo, B. subtilis DE111
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of CES for Fibromyalgia

NCT04115033
View directory record Official record
Conditions
Fibromyalgia
Interventions
Alpha-stim
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 30, 2026, 5:47 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

NCT06538584
View directory record Official record
Conditions
Enhanced Recovery After Surgery in a Pediatric Population
Interventions
Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05237284
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 30, 2026, 5:47 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

NCT04412252
View directory record Official record
Conditions
COVID-19
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Hartford, Connecticut • Iowa City, Iowa • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 30, 2026, 5:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

NCT07220252
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo, Fingolimod
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Setria Performance Blend Supplementation

NCT04090138
View directory record Official record
Conditions
Healthy
Interventions
Setria performance blend, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 30 Years · Male only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 30, 2026, 5:47 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

NCT06925919
View directory record Official record
Conditions
Rift Valley Fever
Interventions
IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3, IDB-011 dose level 4, IDB-011 dose level 5, Placebo
Drug · Other
Lead sponsor
IDBiologics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Recruiting Phase 4 Interventional

GLP-1R Actions on Muscle and the Skeleton

NCT07154719
View directory record Official record
Conditions
Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
Interventions
Tirzepatide, Lifestyle toolkit
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 30, 2026, 5:47 PM EDT